Cellogen Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
3
Cellogen Therapeutics General Information
Description
Provider of cell and gene therapy research and development services intended to create curative treatments for cancers and inherited blood disorders. The company applies advanced cellular engineering and gene manipulation approaches, including the development of third and fourth-generation chimeric antigen receptor-based cellular constructs, bi-specific immune targeting mechanisms, stem cell modification techniques, and gene editing methodologies, enabling healthcare systems, clinicians, and patients to access more precise, long-lasting, and cost-efficient therapeutic options for hematological malignancies, solid tumors, and hemoglobinopathies.
Contact Information
Website
www.cellogentherapeutics.comCorporate Office
- Floor-9, Magnus Tower
- Sector-73
- Noida, Uttar Pradesh 201307
- India
Corporate Office
- Floor-9, Magnus Tower
- Sector-73
- Noida, Uttar Pradesh 201307
- India
Cellogen Therapeutics Timeline
Cellogen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cellogen Therapeutics Comparisons
Industry
Financing
Details
Cellogen Therapeutics Competitors (1)
One of Cellogen Therapeutics’s competitors is GLS Pharma, a Corporate Backed or Acquired company based in New Delhi, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GLS Pharma | Corporate Backed or Acquired | New Delhi, India |
Cellogen Therapeutics Patents
Cellogen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022326908-A1 | Chimeric antigen receptors (car) for b cell malignancies | Pending | 12-Aug-2021 | ||
| CA-3228773-A1 | Chimeric antigen receptors (car) for b cell malignancies | Pending | 12-Aug-2021 | ||
| EP-4384549-A1 | Chimeric antigen receptors (car) for b cell malignancies | Inactive | 12-Aug-2021 | ||
| US-20240343775-A1 | Chimeric antigen receptors (car) for b cell malignancies | Pending | 12-Aug-2021 | ||
| WO-2023017544-A1 | Chimeric antigen receptors (car) for b cell malignancies | Inactive | 12-Aug-2021 | C07K14/7051 |
Cellogen Therapeutics Signals
Cellogen Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cellogen Therapeutics FAQs
-
When was Cellogen Therapeutics founded?
Cellogen Therapeutics was founded in 2021.
-
Where is Cellogen Therapeutics headquartered?
Cellogen Therapeutics is headquartered in Noida, India.
-
What is the size of Cellogen Therapeutics?
Cellogen Therapeutics has 22 total employees.
-
What industry is Cellogen Therapeutics in?
Cellogen Therapeutics’s primary industry is Biotechnology.
-
Is Cellogen Therapeutics a private or public company?
Cellogen Therapeutics is a Private company.
-
What is Cellogen Therapeutics’s current revenue?
The current revenue for Cellogen Therapeutics is .
-
How much funding has Cellogen Therapeutics raised over time?
Cellogen Therapeutics has raised $3.8M.
-
Who are Cellogen Therapeutics’s investors?
Kotak Alternate Assets Managers, Saudi Biotechnology Accelerator, and Natco Pharma have invested in Cellogen Therapeutics.
-
Who are Cellogen Therapeutics’s competitors?
GLS Pharma is a competitor of Cellogen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process